Letter to the Editor
Low-Dose Azathioprine Effectively Suppresses Clinical and Immunological Manifestations of Generalized Myasthenia
Abstract
To the Editor:
Azathioprine (AZT) is the treatment of choice for long-term immunosuppression in patients with myasthenia gravis (MG).1,2 There is some evidence that reduction of the standard dosage is ineffective, but some studies even report ineffectivity of the standard AZT dosage for generalized MG.3 We show that low-dose AZT may also effectively suppress acetylcholine-receptor antibodies (AchR-abs) and clinical manifestations of generalized MG.
This content is limited to qualifying members.
Existing members, please login first
If you have an existing account please login now to access this article or view purchase options.
Purchase only this article ($25)
Create a free account, then purchase this article to download or access it online for 24 hours.
Purchase an SMJ online subscription ($75)
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
Purchase a membership plan (fees vary)
Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.